DelveInsight’s “Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Paroxysmal Nocturnal Hemoglobinuria, historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Paroxysmal Nocturnal Hemoglobinuria market report provides current treatment practices, emerging drugs, Paroxysmal Nocturnal Hemoglobinuria market share of the individual therapies, and current and forecasted Paroxysmal Nocturnal Hemoglobinuria market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Paroxysmal Nocturnal Hemoglobinuria treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Paroxysmal Nocturnal Hemoglobinuria market.
Some of the key facts of the Paroxysmal Nocturnal Hemoglobinuria Market Report:
Key Benefits of the Report:
Got queries? Click here to know more about the Paroxysmal Nocturnal Hemoglobinuria Market Landscape
Paroxysmal Nocturnal Hemoglobinuria Overview
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease of the blood. This disease is due to mutation of the X-linked gene phosphatidylinositol glycan class A (PIGA), leading to deficiency in the glycosylphosphatidylinositol (GPI) protein, which is responsible for anchoring other protein moieties to the surface of erythrocytes.
The appropriate treatment for PNH depends on the severity of the symptoms. Some patients will experience few or no symptoms from PNH and do not require treatment other than folic acid and sometimes iron supplementation to increase red blood cell production. For symptomatic PNH patients, the mainstay treatment is the drug eculizumab (Soliris). It is a monoclonal antibody that inhibits C5 in the terminal complement cascade, interrupting RBC destruction. It reduces the risk of thrombosis and improves the quality of life in PNH patients. The treatment landscape of PNH is highly active with recent launches of approved drugs. In May 2021, US FDA approved Empaveli (pegcetacoplan) injection to treat adults with PNH. Empoli is the first PNH treatment that binds to complement protein C3. Ultomiris, a drug approved in 2018 for the treatment of PNH in adults, gained expanded access to include children (one month of age and older) and adolescents with PNH, in June 2021. Ultomiris is the first and only medicine approved in US to treat children and adolescents with PNH. Both of these drugs were given priority review by US FDA.
Paroxysmal Nocturnal Hemoglobinuria Epidemiological Insights
Paroxysmal Nocturnal Hemoglobinuria Epidemiological Segmentation
Paroxysmal Nocturnal Hemoglobinuria Market Outlook
The Paroxysmal Nocturnal Hemoglobinuria market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Paroxysmal Nocturnal Hemoglobinuria market trends by analyzing the impact of current Paroxysmal Nocturnal Hemoglobinuria therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Paroxysmal Nocturnal Hemoglobinuria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Paroxysmal Nocturnal Hemoglobinuria market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Paroxysmal Nocturnal Hemoglobinuria market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Paroxysmal Nocturnal Hemoglobinuria Market Landscape
Paroxysmal Nocturnal Hemoglobinuria Key Companies
Paroxysmal Nocturnal Hemoglobinuria Therapies
Table of Contents
Click here to read more about the Paroxysmal Nocturnal Hemoglobinuria market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/